title: Should young patients with e19a2 type BCR/ABL rearrangement undergo stem cell transplantation?
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Nakamura
authors.forename: Seishi
authors.initials: S
authors.lastname: Ogawa
authors.forename: Koji
authors.initials: K
authors.lastname: Izutsu
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Imai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Maki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yamagata
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.forename: Hisamaru
authors.initials: H
authors.lastname: Hirai
mesh_terms: D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015321:Gene Rearrangement; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy; D008875:Middle Aged
chemical_list: D016044:Fusion Proteins, bcr-abl